scholarly journals Giant cell tumor of the tendon sheath: Magnetic resonance imaging findings in 38 patients

2017 ◽  
Vol 13 (6) ◽  
pp. 4459-4462 ◽  
Author(s):  
Chao Wang ◽  
Rui-Rui Song ◽  
Ping-Ding Kuang ◽  
Liu-Hong Wang ◽  
Min-Ming Zhang
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Tendon Sheath ◽  
Cell Tumor ◽  
Imaging Findings ◽  
Resonance Imaging

Giant Cell Tumor of the Flexor Hallucis Longus Tendon Sheath

2011 ◽  
Vol 101 (2) ◽  
pp. 187-189 ◽  
Author(s):  
Jeff Findling ◽  
Natalie K. LaScola ◽  
Thomas W. Groner
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Tendon Sheath ◽  
Cell Tumor ◽  
Flexor Hallucis Longus ◽  
Resonance Imaging ◽  
Longus Tendon ◽  
Complete Surgical Excision

Giant cell tumor of tendon sheath is infrequently documented in the foot and even less near the ankle. This case report involves such a tumor of the flexor hallucis longus tendon presenting at the posterior ankle. Diagnosis was aided by magnetic resonance imaging, and treatment consisted of complete surgical excision. Pathologic examination verified the diagnosis of giant cell tumor of tendon sheath, and follow-up magnetic resonance imaging revealed no remnants or recurrence of tumor 1 year after surgery. (J Am Podiatr Med Assoc 101(2): 187–189, 2011)

Rare Giant Cell Tumor of the Distal Flexor Digitorum Longus Tendon Sheath and Early Diagnosis with Use of Magnetic Resonance Imaging

2017 ◽  
Vol 107 (4) ◽  
pp. 333-336 ◽  
Author(s):  
Michael Levi ◽  
Jordan Crafton
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Early Recognition ◽  
Tendon Sheath ◽  
Cell Tumor ◽  
The Body ◽  
Foot And Ankle ◽  
Resonance Imaging

Giant-cell tumor of the tendon sheath (GCT-TS) is an uncommon occurrence for a foot and ankle surgeon. However, there is a need to recognize the symptoms of typical and atypical presentations of this pathology. These benign neoplasms are recognized clinically as a soft-tissue mass that is usually painless and palpable. The foot and ankle account for only 3% to 5% of all GCT-TS in the body, with most being located in the hand. Giant cell tumor in the tendon sheath occurring in the foot and ankle is usually encountered on the lateral ankle and dorsum of the foot, occupying the extensor tendons. Additionally, it is commonly misdiagnosed clinically. This case study illustrates how early use of magnetic resonance imaging decreased patient morbidity with early recognition and excision of GCT-TS.

Differential diagnosis of fibroma of tendon sheath and giant cell tumor of tendon sheath in the finger using signal intensity on T2 magnetic resonance imaging

2020 ◽  
pp. 028418512097691
Author(s):  
Makoto Emori ◽  
Hiroyuki Takashima ◽  
Kousuke Iba ◽  
Tomoko Sonoda ◽  
Takashi Oda ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Differential Diagnosis ◽  
Magnetic Resonance ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Signal Intensity ◽  
Characteristic Curve ◽  
Tendon Sheath ◽  
Cell Tumor ◽  
Resonance Imaging

Background The differential diagnosis of fibroma of tendon sheath (FTS) and giant cell tumor of tendon sheath (GCTTS) on the basis of clinical and radiographic characteristics remains difficult. Purpose To evaluate the quantitative measurement of signal intensity (SI) obtained by magnetic resonance imaging (MRI) for the differential diagnosis of FTS and GCTTS in just the finger. Material and Methods We retrospectively identified patients with FTS (n = 6) and GCTTS (n = 22) of the finger who were treated at our hospitals between April 2011 and August 2019. Two researchers independently reviewed the MRIs and measured the regions of interest (ROIs) in the tumor and flexor tendon from the same image. The SI ratio obtained for the tumor and tendon ROIs was measured and compared using receiver-operating characteristic curve analyses. Sensitivity and specificity analyses were performed. Results The SI ratios (mean ± SD) of FTS and GCTTS were 1.83 ± 0.64 and 6.34 ± 3.16 for researcher 1 and 1.82 ± 0.60 and 6.10 ± 3.22 for researcher 2, respectively. The areas under the curve were 0.970 and 0.970 for researchers 1 and 2, respectively. The cut-off values of the SI ratio as determined by researchers 1 and 2 for differentiating FTS from GCTTS were 3.00 and 3.00, respectively (sensitivity = 95.5%, specificity = 100%). Conclusions The SI ratio is useful for differentiating FTS from GCTTS independent of a combination of tumor signal and shape.

scholarly journals Diagnosis of Giant Cell Tumor of the Tendon Sheath Using Multiecho Gradient-Echo Sequence: the “Superblooming Artifact”

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Michele Gaeta ◽  
Giuseppe Cicero ◽  
Luca Fiorillo ◽  
Sergio Vinci ◽  
Alfredo Blandino ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Tendon Sheath ◽  
Cell Tumor ◽  
Resonance Imaging ◽  
Gradient Echo ◽  
Susceptibility Artifacts ◽  
Magnetic Resonance Imaging Mri

Giant cell tumor of the tendon sheath is a tumor, which affects mainly the hands of people aged 30 to 50 years with a female prevalence. Magnetic resonance imaging (MRI) is essential for diagnosis and treatment planning. The aim of this study is to evaluate the efficacy of multiecho gradient-echoes (MeGE) sequence in detecting hemosiderin which is the hallmark of this tumor. MRIs were performed in a sample of 11 patients with a mean age of 45. With the proposed protocol, all readers were able to detect the susceptibility artifacts due to the presence of hemosiderin. MeGE sequence allows to highlight the presence of hemosiderin, and the use of 3 echo times (ET) (8, 16, and 24 ms) is suggested.

The role of magnetic resonance imaging in giant cell tumor of bone

1987 ◽  
Vol 16 (8) ◽  
pp. 635-643 ◽  
Author(s):  
Steven D. Herman ◽  
Mamed Mesgarzadeh ◽  
Akbar Bonakdarpour ◽  
Murray K. Dalinka
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Resonance Imaging

scholarly journals A Pilot Evaluation of Magnetic Resonance Imaging Characteristics Seen With Primary Soft Tissue Giant Cell Tumor in 2 patients

2019 ◽  
Author(s):  
Lina Zhang ◽  
Jianyun Kang ◽  
Kai Zhang ◽  
Ailian Liu ◽  
Huali Wang ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Soft Tissue ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Lesion Size ◽  
Cell Tumor ◽  
Resonance Imaging ◽  
Adc Value ◽  
Dce Mri

Abstract Background Primary soft tissue giant cell tumor (GCT-ST) is a rare tumor with low malignant potential. Here we reported two cases of patients with soft tissue giant cell tumor in the limb, including their clinical and imaging findings (conventional Magnetic resonance imaging (MRI) and Diffusion weighted imaging (DWI)).Methods This retrospective study included two pathology-confirmed GCT-ST patients. Plain MRI, dynamic contrast enhancement MRI (DCE-MRI), and DWI were performed with a 3.0T whole-body MR scanner before surgery. The following characteristics of lesion were recorded: signal intensity on T 1 FSPGR and T 2 WI, morphology, maximum lesion size, time intensity curve (TIC) on DCE-MRI, and apparent diffusion coefficient (ADC) value from DWI.Results The maximum lesion size ranged from 4.0 cm to 6.0 cm. Signal intensities of all lesions were heterogeneous on T 1 FSPGR and T 2 WI. Nodular enhancements were observed for all lesions with either oval or irregular shapes on MRI. All lesion margins were blurred, and internal enhancements were heterogeneous on DCE-MRI. TIC appeared with a slow increase type. Lesions on DWI (b=500s/mm 2 ) were hyperintense with an higher mean ADC value of 2.19×10 −3 mm 2 /s compared to surrounding normal soft tissue (1.03×10 −3 mm 2 /s).Conclusions DWI may be a useful tool for differentiating benign soft tissue mass from giant cell-rich soft tissue neoplasms or malignant tumors.

Utility of intraoperative magnetic resonance imaging for giant cell tumor of bone after denosumab treatment: a pilot study

2021 ◽  
pp. 028418512198951
Author(s):  
Taisuke Furuta ◽  
Tadahiko Kubo ◽  
Tomohiko Sakuda ◽  
Taiichi Saito ◽  
Kaoru Kurisu ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Tumor Tissue ◽  
Residual Tumor ◽  
Cell Tumor ◽  
Resonance Imaging ◽  
Intraoperative Magnetic Resonance Imaging ◽  
Denosumab Treatment

Background Giant cell tumor of bone (GCTB) is an intermediate but locally aggressive neoplasm. Current treatment of high-risk GCTB involves administration of denosumab, which inhibits bone destruction and promotes osteosclerosis. However, denosumab monotherapy is not a curative treatment for GCTB and surgical treatment remains required. Denosumab treatment complicates surgery, and the recurrence rate of GCTB is high (20%–30%). Purpose To examine the utility of intraoperative magnetic resonance imaging (iMRI) for detection and reduction of residual tumor after denosumab treatment and to investigate the utility of iMRI, which is not yet widely used. Material and Methods We enrolled five patients who received denosumab for a median period of eight months (range 6–12 months). Surgery was performed when the degree of osteosclerosis around the articular surface was deemed appropriate. We performed iMRI using a modified operation table to identify residual tumor after initial curettage and evaluated the rate of detection of residual tumor by iMRI, intraoperative and postoperative complications, exposure time of iMRI, and operation time. Results Suspected residual tumor tissue was identified in all five cases and was confirmed by histopathology after additional curettage. The rate of detection of residual tumor by iMRI was 100%. Residual tumor was located in sites which were difficult to remove due to osteosclerosis. The iMRI was performed safely and without trouble. During the median follow-up period of 10 months (range 6–24 months), no adverse events or recurrences occurred. Conclusion Intraoperative MRI could contribute to the reduction of residual tumor tissue and it may prevent recurrence of GCTB after denosumab therapy.

Sign in / Sign up

Export Citation Format

Share Document